[EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2005090333A1
公开(公告)日:2005-09-29
Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
Fluoride-ion-mediated reaction of trimethylsilylacetylene with carbonylcompounds has been thoroughly studied. The products of addition to the CO bond were obtained in 15–66% yield, their subsequent silylation and addition to the second molecule of the carbonylcompound being observed. It has been found that terminal aryl and hetaryl acetylenes undergo silylation in a two-phase-system Me3SiCCH/CsF/18-crown-6
The CsF–18-crown-6 mediated reactions of disubstitutedacetylenes Me3SiCCMMe3 (M=C, Si, Ge, Sn) with phenylacetylene and 2-methyl-5-pyridylacetylene in benzene have been studied. The first step of the reaction is the deprotonation of aryl acetylene by F−-ion. The carbanion formed interacts with the disubstitutedacetylene. The silylated, germylated and stannylated acetylenes were formed in yields 26–91%
[EN] 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] 5-ALCYNYL PYRIMIDINES ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011092197A1
公开(公告)日:2011-08-04
The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.